Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasushi Yamashita is active.

Publication


Featured researches published by Yasushi Yamashita.


Journal of Pharmacy and Pharmacology | 1996

Amelioration of Disordered Hepatic Protein Synthesis by the Deleted Form of Hepatocyte Growth Factor in Models of Liver Failure in Rats

Hiroaki Masunaga; Nobuaki Fujise; Akira Shiota; Yasushi Yamashita; Hiroshi Yasuda; Kanji Higashio

Because the liver plays an important role in protein synthesis and cholesterol metabolism and reductions in these functions are observed in almost all hepatic disorders, the effects of the deleted form of hepatocyte growth factor (dHGF) on disordered hepatic protein synthesis were studied in various liver‐injured rat models using Wistar male rats.


Surgery | 1999

Deleted form of hepatocyte growth factor ameliorates the mortality rate of severe thermal injury in rats

Hirohiko Arisawa; Yasushi Yamashita; Hiromi Ogawa; Hiroaki Masunaga; Kanji Higashio

BACKGROUND The modulating effects of the deleted form of hepatocyte growth factor (dHGF) on burn-induced mortality rates and hepatic protein synthesis were studied in rats. METHODS Rats were anesthetized, subjected to a 40% full-thickness scald burn, and divided into 2 groups receiving dHGF and vehicle. RESULTS In normal rats, dHGF-treatment (1 mg/kg intravenously, twice daily) for 5 days increased the circulating plasma volume. In burned rats that were receiving vehicle, the survival rate on day 23 after the burn was 27%. The serum albumin levels were decreased and did not reverse to the normal levels until day 23 after the burn. Serum alpha 2-concentration in the injured rats was increased, whereas serum levels of transferrin, total protein, and high-density lipoprotein-cholesterol were decreased. The treatment of animals with dHGF (1 mg/kg intravenously, 3 times daily) for 3 days increased the survival rate on day 23 by 64%. In the animals treated with dHGF for 3 or 6 days, serum alpha 1-, alpha 2-, and beta-globulin concentrations were increased by the dHGF treatment. The serum levels of albumin, transferrin, total protein, and high-density lipoprotein-cholesterol reversed to normal levels or higher. CONCLUSIONS Our data show that dHGF treatment may attenuate the decrease of the circulating plasma volume after burn and reduce a high risk of burn shock. It is also indicated that dHGF accelerates synthesis of not only acute-phase reactants but also other hepatic proteins such as albumin and transferrin on severe burn injury. These findings suggest that the appropriate upregulation of hepatic protein synthesis induced by dHGF may accelerate the physiologic recovery process after thermal injury and contribute to ameliorating the burn-induced death.


Shock | 2001

Pretreatment with a deleted form of hepatocyte growth factor (DHGF) prevents the mortality of plasma-loss-induced hypovolemic shock in rats

Hirohiko Arisawa; Kenji Fukui; Eiichi Imai; Yasushi Yamashita; Yoshinori Iga; Hiroaki Masunaga

Severe trauma, infection, burn, pancreatitis and major surgery often induce circulatory collapse leading to multiple organ failure and death. It is hypothesized that therapy for the attenuation of circulatory collapse may improve the prognosis in these diseases. Previous work has documented that pretreatment with a deleted form of hepatocyte growth factor (dHGF) in normal rats increases the circulating plasma volume that reflects its accelerating action of hepatic protein synthesis. Therefore, the effects of pretreatment with dHGF on hypovolemic shock models were studied in rats. Rats were intravenously administered dHGF (1 mg/kg, twice daily for 5-6 days) or vehicle, and subjected to a 25% total body surface area full-thickness burn or a trypsin-induced acute pancreatitis. In rats that were receiving vehicle, survival rates on day 7 after injury induction were 12% in the burn model and 5% in the pancreatitis model, respectively. In both models, hematocrit values were apparently increased and circulating plasma volumes were decreased compared to sham-operated rats at 6 h after injury induction. The pretreatment of animals with dHGF increased the survival rates on day 7 to 40% in the burn model and 29% in the pancreatitis model. dHGF-treatment in normal rats decreased the hematocrit values and increased the circulating plasma volumes, and these changes of hematocrit value and circulating plasma volume were also maintained after injury induction. These findings suggest that dHGF pretreatment prevents the mortality in the severe burn and acute pancreatitis, and that its effect may contribute to ameliorating the progressing of plasma-loss-induced hypovolemia.


The Journal of Antibiotics | 2002

SNF4435C and D, novel immunosuppressants produced by a strain of Streptomyces spectabilis. III. Immunosuppressive efficacy

Kazuhiko Kurosawa; Kosaku Takahashi; Nobuaki Fujise; Yasushi Yamashita; Naohiro Washida; Eisuke Tsuda


Journal of Veterinary Medical Science | 1998

Effects of the Deleted Form of Hepatocyte Growth Factor on Serum Hyaluronate Levels in Rats with Liver Cirrhosis

Yasushi Yamashita; Akira Shiota; Nobuaki Fujise; Hiromi Ogawa; Hiroaki Masunaga; Hiroshi Yasuda; Kanji Higashio


Pharmacological Research | 2000

A deleted form of human hepatocyte growth factor stimulates hepatic lipogenesis and lipoprotein synthesis in rats

Akira Shiota; Yasushi Yamashita; Nobuaki Fujise; Hiroaki Masunaga; Hiroshi Yasuda; Kanji Higashio


Liver | 2008

Deleted form of hepatocyte growth factor (dHGF) increases the number of platelets in rats with liver cirrhosis

Hiroaki Masunaga; Nobuaki Fujise; Yasushi Yamashita; Akira Shiota; Hiroshi Yasuda; Kanji Higashio


Liver | 2002

Reduction of monocrotaline-induced hepatic injury by deleted variant of hepatocyte growth factor (dHGF) in rats.

Yasushi Yamashita; Nobuaki Ishibashi Heights Fujise; Eiichi Imai; Hiroaki Masunaga; Nobuaki Fujise


Biochemical and Biophysical Research Communications | 1999

A Mutant of Deleted Variant of Hepatocyte Growth Factor (dHGF) with Alanine Substitution in the N-Terminal Basic Region Has Higher Activityin Vivo

Masahiko Kinosaki; Kyoji Yamaguchi; Yasushi Yamashita; Yasuhiro Uematsu; Hiromi Aihara; Hiroaki Masunaga; Tomonori Morinaga; Kanji Higashio


Archive | 1995

Mutantes de tecf.

Masaaki Goto; Kanji Higashio; Masahiko Kinosaki; Fumie Kobayashi; Masatsugu Ueda; Kyoji Yamaguchi; Yasushi Yamashita

Collaboration


Dive into the Yasushi Yamashita's collaboration.

Top Co-Authors

Avatar

Kanji Higashio

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge